Conatumumab (AMG 655) coated nanoparticles for targeted pro-apoptotic drug delivery

Biomaterials

Volumn 32, Issue 33, 2011, Pages 8645-8653

  Fay, Francois ^a   McLaughlin, Kirsty M ^a   Small, Donna M ^a   Fennell, Dean A ^a   Johnston, Patrick G ^a   Longley, Daniel B ^a   Scott, Christopher J ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

C FLIP; Cancer; Caspase pathway; Conatumumab; DR5; Nanoparticles

Indexed keywords

C-FLIP; CANCER; CASPASES; CONATUMUMAB; DR5;

CELL DEATH; CYTOTOXICITY; DISEASES; DRUG DELIVERY; NANOPARTICLES;

ANTIBODIES;

CAMPTOTHECIN; CONATUMUMAB; DEATH RECEPTOR 5; NANOPARTICLE; POLYGLACTIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SYNTHESIS; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; APOPTOSIS; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; HUMANS; MICROSCOPY, ELECTRON, SCANNING; MICROSCOPY, FLUORESCENCE; NANOPARTICLES;

EID: 80052960859     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.07.065     Document Type: Article

References (64)

1. Sun B., Ranganathan B., Feng S.S. Multifunctional poly(D, L-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer. Biomaterials 2008, 29:475-486.
2. Kocbek P., Obermajer N., Cegnar M., Kos J., Kristl J. Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody. J Control Release 2007, 120:18-26.
3. Obermajer N., Kocbek P., Repnik U., Kuznik A., Cegnar M., Kristl J., et al. Immunonanoparticles - an effective tool to impair harmful proteolysis in invasive breast tumor cells. FEBS J 2007, 274:4416-4427.
4. Kou G., Gao J., Wang H., Chen H., Li B., Zhang D., et al. Preparation and Characterization of Paclitaxel-loaded PLGA nanoparticles coated with cationic SM5-1 single-chain antibody. J Biochem Mol Biol 2007, 40:731-739.
5. Chen H., Gao J., Lu Y., Kou G., Zhang H., Fan L., et al. Preparation and characterization of PE38KDEL-loaded anti-HER2 nanoparticles for targeted cancer therapy. J Control Release 2008, 128:209-216.
6. Cirstoiu-Hapca A., Buchegger F., Lange N., Bossy L., Gurny R., Delie F. Benefit of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in the treatment of disseminated ovarian cancer: therapeutic efficacy and biodistribution in mice. J Control Release 2010, 144:324-331.
7. Gao X., Cui Y., Levenson R.M., Chung L.W., Nie S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol 2004, 22:969-976.
8. Wu G., Yang W., Barth R.F., Kawabata S., Swindall M., Bandyopadhyaya A.K., et al. Molecular targeting and treatment of an epidermal growth factor receptor-positive glioma using boronated cetuximab. Clin Cancer Res 2007, 13:1260-1268.
9. Shukla R., Thomas T.P., Peters J.L., Desai A.M., Kukowska-Latallo J., Patri A.K., et al. HER2 specific tumor targeting with dendrimer conjugated anti-HER2 mAb. Bioconjug Chem 2006, 17:1109-1115.
10. Fesik S.W. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 2005, 5:876-885.
11. Papenfuss K., Cordier S.M., Walczak H. Death receptors as targets for anti-cancer therapy. J Cell Mol Med 2008, 12:2566-2585.
12. Chan F.K., Chun H.J., Zheng L., Siegel R.M., Bui K.L., Lenardo M.J. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 2000, 288:2351-2354.
13. Medema J.P., Scaffidi C., Kischkel F.C., Shevchenko A., Mann M., Krammer P.H., et al. FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). EMBO J 1997, 16:2794-2804.
14. Ashkenazi A., Dixit V.M. Death receptors: signaling and modulation. Science 1998, 281:1305-1308.
15. Duiker E.W., van der Zee A.G., de Graeff P., Boersma-van Ek W., Hollema H., de Bock G.H., et al. The extrinsic apoptosis pathway and its prognostic impact in ovarian cancer. Gynecol Oncol 2010, 116:549-555.
16. Bavi P., Prabhakaran S.E., Abubaker J., Qadri Z., George T., Al-Sanea N., et al. Prognostic significance of TRAIL death receptors in Middle Eastern colorectal carcinomas and their correlation to oncogenic KRAS alterations. Mol Cancer 2010, 9:203-216.
17. Sanlioglu A.D., Korcum A.F., Pestereli E., Erdogan G., Karaveli S., Savas B., et al. TRAIL death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma. Int J Radiat Oncol Biol Phys 2007, 69:716-723.
18. McLornan D.P., Barret T., Cumminngs R., McDermott U., McDowell C., Conlon S.J., et al. Prognostic significance of TRAIL signaling molecules in stage II and III colorectal cancer. Clin Cancer Res 2010, 16:3442-3451.
19. Kaplan-Lefko P.J., Graves J.D., Zoog S.J., Pan Y., Wall J., Branstetter D.G., et al. Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types. Cancer Biol Ther 2010, 9:618-631.
20. Doi T., Murakami H., Ohtsu A., Fuse N., Yoshino T., Yamamoto N., et al. Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 2010, 10:1544-1551.
21. Herbst R.S., Kurzrock R., Hong D.S., Valdivieso M., Hsu C.P., Goyal L., et al. A first-in-human study of conatumumab in adult patients with advanced solid tumors. Clin Cancer Res 2010, 16:5883-5891.
22. Longley D.B., Wilson T.R., McEwan M., Allen W.L., McDermott U., Galligan L., et al. c-FLIP inhibits chemotherapy-induced colorectal cancer cell death. Oncogene 2006, 25:838-848.
23. Wilson T.R., McLaughlin K.M., McEwan M., Sakai H., Rogers K.M., Redmond K.M., et al. c-FLIP: a key regulator of colorectal cancer cell death. Cancer Res 2007, 67:5754-5762.
24. Scott C.J., Marouf W.M., Quinn D.J., Buick R.J., Orr S.J., Donnelly R.F., et al. Immunocolloidal targeting of the endocytotic siglec-7 receptor using peripheral attachment of siglec-7 antibodies to poly(lactide-co-glycolide) nanoparticles. Pharm Res 2008, 25:135-146.
25. McCarron P.A., Marouf W.M., Donnelly R.F., Scott C. Enhanced surface attachment of protein-type targeting ligands to poly(lactide-co-glycolide) nanoparticles using variable expression of polymeric acid functionality. J Biomed Mater Res A 2008, 87:873-884.
26. Galligan L., Longley D.B., McEwan M., Wilson T.R., McLaughlin K., Johnston P.G. Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP. Mol Cancer Ther 2005, 4:2026-2036.
27. Fay F., Quinn D.J., Gilmore B.F., McCarron P.A., Scott C.J. Gene delivery using dimethyldidodecylammonium bromide-coated PLGA nanoparticles. Biomaterials 2010, 31:4214-4222.
28. Neri S., Mariani E., Meneghetti A., Cattini L., Facchini A. Calcein-acetyoxymethyl cytotoxicity assay: standardization of a method allowing additional analyses on recovered effector cells and supernatants. Clin Diagn Lab Immunol 2001, 8:1131-1135.
29. Redmond K.M., Wilson T.R., Johnston P.G., Longley D.B. Resistance mechanisms to cancer chemotherapy. Front Biosci 2008, 13:5138-5154.
30. Giovanella B.C., Stehlin J.S., Wall M.E., Wani M.C., Nicholas A.W., Liu L.F., et al. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 1989, 246:1046-1048.
31. Goldwasser F., Shimizu T., Jackman J., Hoki Y., O'Connor P.M., Kohn K.W., et al. Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells. Cancer Res 1996, 56:4430-4437.
32. Walczak H., Krammer P.H. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp Cell Res 2000, 256:58-66.
33. Ashkenazi A., Pai R.C., Fong S., Leung S., Lawrence D.A., Marsters S.A., et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999, 104:155-162.
34. Walczak H., Miller R.E., Ariail K., Gliniak B., Griffith T.S., Kubin M., et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999, 5:157-163.
35. Kelley S.K., Harris L.A., Xie D., Deforge L., Totpal K., Bussiere J., et al. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 2001, 299:31-38.
36. Wajant H., Pfizenmaier K., Scheurich P. TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy. Apoptosis 2002, 7:449-459.
37. Bonavida B., Ng C.P., Jazirehi A., Schiller G., Mizutani Y. Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: the trail to non-toxic cancer therapeutics (review). Int J Oncol 1999, 15:793-802.
38. Shankar S., Srivastava R.K. Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications. Drug Resist Updat 2004, 7:139-156.
39. Gliniak B., Le T. Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. Cancer Res 1999, 59:6153-6158.
40. Johnstone R.W., Frew A.J., Smyth M.J. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 2008, 8:782-798.
41. Adams C., Totpal K., Lawrence D., Marsters S., Pitti R., Yee S., et al. Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5. Cell Death Differ 2008, 15:751-761.
42. Zeng Y., Wu X.X., Fiscella M., Shimada O., Humphreys R., Albert V., et al. Monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) induces apoptosis in primary renal cell carcinoma cells in vitro and inhibits tumor growth in vivo. Int J Oncol 2006, 28:421-430.
43. Wu K., Liu J., Johnson R.N., Yang J., Kopecek J. Drug-free macromolecular therapeutics: induction of apoptosis by coiled-coil-mediated cross-linking of antigens on the cell surface. Angew Chem Int Ed Engl 2010, 49:1451-1455.
44. Jiang W., Kim B.Y., Rutka J.T., Chan W.C. Nanoparticle-mediated cellular response is size-dependent. Nat Nanotechnol 2008, 3:145-150.
45. Fassberg J., Stella V.J. A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J Pharm Sci 1992, 81:676-684.
46. Potmesil M. Camptothecins: from bench research to hospital wards. Cancer Res 1994, 54:1431-1439.
47. Yang X.X., Hu Z.P., Xu A.L., Duan W., Zhu Y.Z., Huang M., et al. A mechanistic study on reduced toxicity of irinotecan by coadministered thalidomide, a tumor necrosis factor-alpha inhibitor. J Pharmacol Exp Ther 2006, 319:82-104.
48. Numbenjapon T., Wang J., Colcher D., Schluep T., Davis M.E., Duringer J., et al. Preclinical results of camptothecin-polymer conjugate (IT-101) in multiple human lymphoma xenograft models. ClinCancer Res 2009, 15:4365-4373.
49. Lu J., Liong M., Zink J.I., Tamanoi F. Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs. Small 2007, 3:1341-1346.
50. Koo O.M., Rubinstein I., Onyuksel H. Camptothecin in sterically stabilized phospholipid micelles: a novel nanomedicine. Nanomedicine 2005, 1:77-84.
51. Loch-Neckel G., Nemen D., Puhl A.C., Fernandes D., Stimamiglio M.A., Alvarez Silva M., et al. Stealth and non-stealth nanocapsules containing camptothecin: in-vitro and in-vivo activity on B16-F10 melanoma. J Pharm Pharmacol 2007, 59:1359-1364.
52. Kunii R., Onishi H., Machida Y. Preparation and antitumor characteristics of PLA/(PEG-PPG-PEG) nanoparticles loaded with camptothecin. Eur J Pharm Biopharm 2007, 67:9-17.
53. Liu J., Jiang Z., Zhang S., Saltzman W.M. Poly(omega-pentadecalactone-co-butylene-co-succinate) nanoparticles as biodegradable carriers for camptothecin delivery. Biomaterials 2009, 30:5707-5719.
54. McCarron P.A., Marouf W.M., Quinn D.J., Fay F., Burden R.E., Olwill S.A., et al. Antibody targeting of camptothecin-loaded PLGA nanoparticles to tumor cells. Bioconjug Chem 2008, 19:1561-1569.
55. Wang S., El-Deiry W.S. Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy. Proc Natl Acad Sci U S A 2003, 100:15095-15100.
56. Ray S., Shyam S., Fraizer G.C., Almasan A. S-phase checkpoints regulate Apo2 ligand/TRAIL and CPT-11-induced apoptosis of prostate cancer cells. Mol Cancer Ther 2007, 6:1368-1378.
57. Kim J.H., Kim Y.S., Park K., Lee S., Nam H.Y., Min K.H., et al. Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice. J Control Release 2008, 127:41-49.
58. Sarfati G., Dvir T., Elkabets M., Apte R.N., Cohen S. Targeting of polymeric nanoparticles to lung metastases by surface-attachment of YIGSR peptide from laminin. Biomaterials 2011, 32:152-161.
59. Dinauer N., Balthasar S., Weber C., Kreuter J., Langer K., von Briesen H. Selective targeting of antibody-conjugated nanoparticles to leukemic cells and primary T-lymphocytes. Biomaterials 2005, 26:5898-5906.
60. Wagner S., Rothweiler F., Anhorn M.G., Sauer D., Riemann I., Weiss E.C., et al. Enhanced drug targeting by attachment of an anti alphav integrin antibody to doxorubicin loaded human serum albumin nanoparticles. Biomaterials 2010, 31:2388-2398.
61. Acharya S., Dilnawaz F., Sahoo S.K. Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy. Biomaterials 2009, 30:5737-5750.
62. Hatakeyama H., Akita H., Ishida E., Hashimoto K., Kobayashi H., Aoki T., et al. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes. Int J Pharm 2007, 342:194-200.
63. Feng B., Tomizawa K., Michiue H., Han X.J., Miyatake S., Matsui H. Development of a bifunctional immunoliposome system for combined drug delivery and imaging in vivo. Biomaterials 2010, 31:4139-4145.
64. Eghtedari M., Liopo A.V., Copland J.A., Oraevsky A.A., Motamedi M. Engineering of hetero-functional gold nanorods for the in vivo molecular targeting of breast cancer cells. Nano Lett 2009, 9:287-291.